Showing results (161-170 of 213) with videos related to

Sort By:
Pageof 22
Urologic Oncology|July 26, 2021
A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II studyYaoYao Pollock, Li Zhang, Stacey A Kenfield, et al.
British Journal of Cancer|May 19, 2023
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomasNitya Raj, Jennifer A Chan, Stephanie J Wang, et al.
The Journal of Clinical Investigation|October 22, 2024
Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancerRu M Wen, Jessica C Stark, G Edward W Marti, et al.
Clinical Colorectal Cancer|March 13, 2026
Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal CancerAndrea Bocobo, Julia Whitman, Bridget P Keenan, et al.
Nature Cancer|April 28, 2026
Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancerChengyi Li, Fang Ke, Hongyi Zhao, et al.
Journal for Immunotherapy of Cancer|December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinomaDouglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Cell|June 5, 2020
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerDavid Y Oh, Serena S Kwek, Siddharth S Raju, et al.
BJU International|April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinomaSumanta K Pal, David F McDermott, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignanciesAmy J Chien, Julie A Illi, Andrew H Ko, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Pageof 22